慢性肾脏病3~5期患者病情程度与α-Klotho、FGF23及钙、磷相关性研究

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (514 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the changes of α-Klotho, fibroblast growth factor 23 (FGF23) and calcium and phosphorus levels in patients with stage 3-5 chronic kidney disease (CKD) and the correlation between CKD and α-Klotho, fibroblast growth factor-23 (FGF23) and calcium and phosphorus metabolism. Methods A total of 20 patients with CKD three to five stage who were admitted to the Department of Nephrology of Hubei Provincial Hospital of Traditional Chinese Medicine from June to December 2018 were selected as the CKD group. Another 22 healthy people were selected as the normal group. The serum levels of α-Klotho, FGF23, parathyroid hormone (PTH), estimation of glomerular filtration rate (eGFR) and calcium and phosphorus were measured in the two groups. Results The serum levels of phosphorus, PTH and FGF23 in the CKD group were higher than those in the normal group, and the levels of calcium, α-Klotho and eGFR were lower than those in the normal group, with statistically significant differences (P ＜ 0.05). Compared with CKD3 stage, serum calcium and α-Klotho levels and eGFR in patients with stage 4 and 5 CKD stage decreased, while phosphorus, FGF23 and PTH levels were increased, with statistically significant differences (P ＜ 0.05). The degree of CKD 3-5 stage disease was positively correlated with phosphorus, PTH, and FGF23 (r = 0.706, 0.963, 0.915, P ＜ 0.05), and negatively correlated with calcium, eGFR, and α-Klotho (r = -0.821, -0.865, -0.718, P ＜ 0.05). Conclusion The bone mineral metabolism disorder in patients with stage CDK 3-5 gradually worsened, and the severity of the disease is closely related to the levels of α-Klotho, FGF23 and calcium and phosphorus.

Key words： Chronic kidney disease α-Klotho Fibroblast growth factor-23 Calcium Phosphorus

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Hong1
	2 LI Yingxia3 WANG Xiaoqin1
	2 HAN Siping1
	2

Cite this article:

CHENG Hong1,2 LI Yingxia3 WANG Xiaoqin1,2 HAN Siping1, et al. Study on the correlation between the condition of chronic kidney disease patients with stage 3-5 and α-Klotho, FGF23, calcium and phosphorus[J]. 中国医药导报, 2020, 17(22): 78-81.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I22/78

[1] Ferenbach DA，Bonventre JV. Acute kidney injury and chronic kidney disease：From the laboratory to the clinic [J]. Nephrol Ther，2016，12 Suppl 1（Suppl 1）：S41- S48.
[2] 王海燕.肾脏病学[M].北京：人民卫生出版社，2016：1746-1758.
[3] Go AS，Chertow GM，Fan D，et al. Chronic kidney disease and the risks of death，cardiovascular events，and hospitalization [J]. N Engl J Med，2004，351：1296-1305.
[4] Mikhail A，Shrivastava R，Richardson O，et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease [J]. BMC Nephrology，2017，118(S1)：c101-c124.
[5] 李颖霞，程虹，王小琴.FGF23在慢性肾脏病中作用的研究进展[J].中国中西医结合肾病杂志，2018，19（8）：741-743.
[6] Leone F，Lofar D，Giqliotti P，et al. Soluble Klotho levels in adult renal transplant recipients are modulated by recombinant human erythropoietin [J]. J Nephrol，2014，27（5）：577-585.
[7] 李婉莎，余毅.慢性肾脏病患者钙磷代谢紊乱及其治疗策略[J].世界临床药物，2018，39（3）：204-210.
[8] 张宇，陈卫东.慢性肾脏病患者钙磷代谢紊乱的研究进展[J].安徽医学，2017，38（8）：1088-1091.
[9] 王丹，巴应贵.慢性肾脏病钙、磷代谢相关影响因素的研究进展[J].世界最新医学信息文摘，2016，16（89）：21，187.
[10] Suki WN，Moore LW. Phosphorus regulation in chronic kidney disease [J]. MDCVJ，2016，12（4 Suppl）：6-9.
[11] 吴艺青，高银龙，陶静，等.黄芪对慢性肾脏病大鼠钙磷代谢及FGF23-Klotho轴的影响[J].南京中医药大学学报，2018，34（2）：118-122.
[12] 王毅.FGF23介导钙磷代谢与慢性肾脏病关系的研究进展[J].世界最新医学信息文摘，2017，17（97）：23-24.
[13] 黄泳璋，肖洁.成纤维细胞生长因子23与慢性肾脏病患者肾功能及钙磷代谢的关系[J].中国实用医药，2017， 12（29）：41-42.
[14] Yuan J，Zou XR，Han SP，et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients： results from the Chinese cohort study of chronic kidney disease（C-STRIDE） [J]. BMC Nephrology，2017，18（1）：23.
[15] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志，2017，37（1）：28-30.
[16] 茅宇烽，朱淳.慢性肾病钙磷代谢状况分析[J].创伤与急危重病医学，2018，6（5）：267-269.
[17] Kuroo M. Endocrine FGFs and Klothos： emerging concepts [J]. Trends Endocrinol Metab，2008，19（7）：239-245.
[18] Hu MC，Kuro-o M，Moe OW. Klotho and chronic kidney disease [J]. Contrib Nephrol，2013，180：47-63.
[19] Komaba H，Kaludjerovic J，Hu DZ，et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation [J]. Kidney Int，2017：S00852538173 01205.
[20] Hu MC，Shi M，Zhang J，et al. Renal Production，Uptake，and Handling of Circulating alphaKlotho [J]. J Am Soc Nephrol，2016，27（1）：79-90.
[21] Lindberg K，Amin R，Moe OW，et al. The kidney is the principal organ mediating klotho effects [J]. J Am Soc Nephrol，2014，25（10）： 2169-2175.
[22] 王君，姜晓燕，丁秀霞.慢性肾脏病患者血清Klotho蛋白、成纤维细胞生长因-23水平与疾病严重程度的相关性分析[J].国际检验医学杂志，2017，38（15）：2079-2081.
[23] 安书强，杨倩，史长生，等.血液灌流串联血液透析滤过改善肾性骨营养不良效果研究[J].武警后勤学院学报：医学版，2013，22（6）： 468-472.
[24] 叶坚旭.老年血液透析患者NT-proBNP水平在干体重评估中的临床意义[J].中国医药科学，2020，10（1）：292-294.
[25] Silver J，Navehmany T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease [J]. Nat Rev Nephrol，2013，9（11）：641-649.
[26] Miyamoto K，Ito M，Tatsumi S，et al. New aspect of renal phos- phatereabsorption：The type IIc sodium-dependent phosphate transporter [J]. Am J Nephrol，2007，27（5）：503-515.
[27] 车琳，戴慧莉，严玉澄.Klotho蛋白在肾脏疾病中的研究进展[J].中国中西医结合肾病杂志，2013，14（11）：1028-1030.
[28] 李佳，魏善斋，孙杰，等.血液透析患者血清klotho蛋白水平与营养状况的关系[J].中国医药导报，2019，16（34）：96-99.
[29] 张宝玉，赵冬，夏维波.成纤维细胞生长因子-23和α-Klotho蛋白在慢性肾脏病中的作用[J].中华骨质疏松和骨矿盐疾病杂志，2015，8（4）： 367-373.